Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CU01-1001 in Type 2 Diabetic Nephropathy Patients With Albuminuria
NCT05718375Phase 2Completed
- Sponsor
- Curacle Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CU01-1001 in diabetic nephropathy (DN) (3 arms), sponsored by Curacle Co., Ltd. Primary endpoint: Change rate of urinary albumin/creatinine ratio at 24 weeks. Started Feb 2023; status: completed.
02
Drugs
CU01-1001
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT05718375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718375.